Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(60.0%)
Phase 4
2(40.0%)
5Total
Phase 3(3)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07345624Phase 4Not Yet Recruiting

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B

Role: collaborator

NCT07345611Phase 4Not Yet Recruiting

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B

Role: collaborator

NCT02025036Phase 3Unknown

Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer

Role: collaborator

NCT03950518Phase 3Unknown

Novel Treatment of Advanced Hepatocellular Carcinoma

Role: collaborator

NCT03940378Phase 3Unknown

Treatment of Advanced Intrahepatic Cholangiocarcinoma

Role: collaborator

All 5 trials loaded